SPECIAL NOTICE
65 -- Notice of Intent to Sole Source - EzPlaz
- Notice Date
- 9/1/2026 12:00:00 AM
- Notice Type
- Special Notice
- NAICS
- 325412
— Pharmaceutical Preparation Manufacturing
- Contracting Office
- DEFENSE HEALTH AGENCY FORT DETRICK MD 21702 USA
- ZIP Code
- 21702
- Solicitation Number
- HT942726QE015
- Response Due
- 9/16/2026 12:00:00 PM
- Archive Date
- 01/01/2027
- Point of Contact
- Timothy Kelly, Shannon Lertora
- E-Mail Address
-
timothy.j.kelly169.civ@health.mil, shannon.p.lertora.civ@health.mil
(timothy.j.kelly169.civ@health.mil, shannon.p.lertora.civ@health.mil)
- Description
- The Defense Health Agency (DHA) Contracting Activity (DHACA), on behalf of the DHA�s Portfolio Acquisition Executive Medical Products (PAE MP), intends to issue a firm-fixed price Indefinite Delivery/Indefinite Quantity contract on a sole source basis under the authority of the Revolutionary Federal Acquisition Regulation (FAR) Overhaul, FAR 6.103-1, only one responsible source and no other supplies or services will satisfy agency requirements, to Vascular Solutions LLC, 6420 Sycamore Ct N, Maple Grove, Minnesota 55369-6032. Vascular Solutions, LLC is the only source able to meet the Government�s requirements. The Government has a has a critical requirement for supply of a Food and Drug Administration (FDA) approved Freeze Dried Plasma (FDP) product for transfusion when plasma is required and other plasma products are not available. The FDA approved Vascular Solutions, LLC FDP product, EZPLAZ�, on 29 July 2026. Vascular Solutions LLC holds the first and only FDA-approved (licensed) FPD product on the market. This Notice of Intent is not a request for competitive proposals and no solicitation document exists for the requirement. Sources interested in responding to this notice are required to submit a capability statement that includes management and technical data and cost information, in sufficient detail and with convincing evidence that clearly demonstrates the capability to perform the required work. Responses must be supported with clear and convincing evidence articulating the ability to provide FDA approved FDP product. Capability statements shall not exceed 5 (8.5 x 11 inch) pages using a font size no smaller than 10-point. All capability statements received by the due date of this notice will be considered by the Government. A request for documentation or additional information or submissions that only ask questions will not be considered as an affirmative response. A determination by the Government not to compete based on responses to this notice is solely within the discretion of the Government. Information received will be considered solely for the purpose of determining whether to conduct a competitive procurement or to proceed with a sole source contract. If no written responses are received by the date listed below, an Indefinite Delivery/Indefinite Quantity contract will be awarded without further remark. Capability statements are due by 3:00 PM local time, 16 September 2026. Capability statements shall be submitted by e-mail ONLY as a Microsoft Word or Adobe PDF attachment to the following address: timothy.j.kelly169.civ@health.mil and shannon.p.lertora.civ@health.mil.
- Web Link
-
SAM.gov Permalink
(https://sam.gov/workspace/contract/opp/5dda764058414494a13827d6b4ad2a6e/view)
- Place of Performance
- Address: MD 21702, USA
- Zip Code: 21702
- Country: USA
- Zip Code: 21702
- Record
- SN07952355-F 20260903/260901230046 (samdaily.us)
- Source
-
SAM.gov Link to This Notice
(may not be valid after Archive Date)
| FSG Index | This Issue's Index | Today's SAM Daily Index Page |